Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jun;11(6):521-34.
doi: 10.1016/S1474-4422(12)70065-0. Epub 2012 May 16.

Diabetic neuropathy: clinical manifestations and current treatments

Brian C Callaghan  1 , Hsinlin T Cheng, Catherine L Stables, Andrea L Smith, Eva L Feldman
Affiliations
Review

Diabetic neuropathy: clinical manifestations and current treatments

Brian C Callaghan et al. Lancet Neurol. 2012 Jun.

Abstract

Diabetic peripheral neuropathy is a prevalent, disabling disorder. The most common manifestation is distal symmetrical polyneuropathy (DSP), but many patterns of nerve injury can occur. Currently, the only effective treatments are glucose control and pain management. While glucose control substantially decreases the development of neuropathy in those with type 1 diabetes, the effect is probably much smaller in those with type 2 diabetes. Evidence supports the use of specific anticonvulsants and antidepressants for pain management in patients with diabetic peripheral neuropathy. However, the lack of disease-modifying therapies for diabetic DSP makes the identification of new modifiable risk factors essential. Growing evidence supports an association between components of the metabolic syndrome, including prediabetes, and neuropathy. Studies are needed to further explore this association, which has implications for the development of new treatments for this common disorder.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

There are no conflicts of interest to declare.

Figures

Figure 1
Figure 1. Patterns of nerve injury in diabetic neuropathy
Many patterns of nerve injury are observed in patients with diabetes. By far the most common neuropathy subtype is distal symmetric polyneuropathy (DSP), which is the focus of this review. However, clinicians should be aware of all potential patterns as they have implications for the evaluation and treatment of these patients. For example, patients with diabetes can develop a radiculopathy without a disc herniation or degenerative changes in the spine. This knowledge could prevent a patient from spine surgery in the case where imaging results are equivocal. Furthermore, patients with diabetes can have more than one pattern of nerve injury, and the clinician needs to ask patients about specific symptoms such as autonomic involvement, which is often overlooked. The following patterns are shown in the figure: (A) DSP, small fiber predominant neuropathy, treatment induced neuropathy (B) radiculoplexopathy, radiculopathy (C) mononeuropathy, mononeuritis multiplex (D) autonomic neuropathy, treatment induced neuropathy. Note that small fiber predominant neuropathy has the same pattern as DSP but that the neurologic examination and electrodiagnostic studies are quite different, which has the potential to lead the clinician astray. Diabetic radiculoplexopathy may be responsive to immunotherapy and in contrast to most nerve injury in patients with diabetes, usually improves with time, . Treatment induced neuropathy is an under-recognized phenomenon. Unlike the other peripheral manifestations of diabetes, this condition is caused by overaggressive control of glucose levels.
Figure 2
Figure 2. Small fiber predominant neuropathy on skin biopsy
(A) Skin biopsy evaluating intra-epidermal nerve fiber density (stained with protein gene product 9.5, 50 micrometer sections) from a 41 year old male without neuropathy. Two nerves are seen crossing the dermal-epidermal junction. (B) Skin biopsy evaluating intra-epidermal nerve fiber density from a 50 year old male with diabetic neuropathy. No nerves are seen crossing the dermal-epidermal junction. (C) Sural nerve biopsy from a 44 year old male with diabetic neuropathy (40X magnification). Biopsy reveals axonal loss of small and large diameter nerves.
Figure 2
Figure 2. Small fiber predominant neuropathy on skin biopsy
(A) Skin biopsy evaluating intra-epidermal nerve fiber density (stained with protein gene product 9.5, 50 micrometer sections) from a 41 year old male without neuropathy. Two nerves are seen crossing the dermal-epidermal junction. (B) Skin biopsy evaluating intra-epidermal nerve fiber density from a 50 year old male with diabetic neuropathy. No nerves are seen crossing the dermal-epidermal junction. (C) Sural nerve biopsy from a 44 year old male with diabetic neuropathy (40X magnification). Biopsy reveals axonal loss of small and large diameter nerves.
Figure 2
Figure 2. Small fiber predominant neuropathy on skin biopsy
(A) Skin biopsy evaluating intra-epidermal nerve fiber density (stained with protein gene product 9.5, 50 micrometer sections) from a 41 year old male without neuropathy. Two nerves are seen crossing the dermal-epidermal junction. (B) Skin biopsy evaluating intra-epidermal nerve fiber density from a 50 year old male with diabetic neuropathy. No nerves are seen crossing the dermal-epidermal junction. (C) Sural nerve biopsy from a 44 year old male with diabetic neuropathy (40X magnification). Biopsy reveals axonal loss of small and large diameter nerves.
Figure 3
Figure 3. Mechanisms of diabetic neuropathy
Factors linked to type 1 diabetes (yellow), type 2 diabetes (blue) and both (green) cause DNA damage, ER stress, mitochondrial dysfunction, apoptosis and loss of neurotrophic signaling. This cell damage can occur in neurons, glial cells and vascular endothelial cells, as well as triggering macrophage activation, all of which can lead to nerve dysfunction and neuropathy. The relative importance of the pathways in this network will vary with cell type, disease profile and time. Abbreviations: AGE, advanced glycation end-products; LDL, low-density lipoprotein; HDL, high-density lipoprotein; FFA, free fatty acids; ROS, reactive oxygen species (red star); ER, endoplasmic reticulum; PI3K, phosphatidylinositol 3-kinase.
Figure 4
Figure 4. Algorithm for the treatment of diabetic painful neuropathy
First and seconds line treatments for diabetic painful neuropathy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bharucha NE, Bharucha AE, Bharucha EP. Prevalence of peripheral neuropathy in the Parsi community of Bombay. Neurology. 1991;41(8):1315–7. - PubMed
    1. Savettieri G, Rocca WA, Salemi G, Meneghini F, Grigoletto F, Morgante L, et al. Prevalence of diabetic neuropathy with somatic symptoms: a door-to-door survey in two Sicilian municipalities. Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology. 1993;43(6):1115–20. - PubMed
    1. Gregg EW, Sorlie P, Paulose-Ram R, Gu Q, Eberhardt MS, Wolz M, et al. Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999–2000 national health and nutrition examination survey. Diabetes Care. 2004;27(7):1591–7. - PubMed
    1. Johannsen L, Smith T, Havsager AM, Madsen C, Kjeldsen MJ, Dalsgaard NJ, et al. Evaluation of patients with symptoms suggestive of chronic polyneuropathy. J Clin Neuromuscul Dis. 2001;3(2):47–52. - PubMed
    1. Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, Manjoo Q, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1989;38(11):1456–61. - PubMed

Publication types

MeSH terms